Openbookopenbook
Equity
StockUS listing USJBPHFPINKHealthcareValue Trap

Jacobio Pharmaceuticals Group Co. Ltd.(JBPHF) Stock Analysis | Healthcare

USD --+0.00%
Reward43Moderate
Risk40Moderate
75%Data
Thin -23% profit margin · Revenue growing 572% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 653.10M
Reward Ratingⓘ43 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ40 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on JBPHF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Jacobio Pharmaceuticals Group Co. Ltd.?

, an investment holding company, engages in the in-house discovery and development of oncology therapies.

AI Brief Pro

The brief on Jacobio Pharmaceuticals Group Co. Ltd.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Jacobio Pharmaceuticals Group Co. Ltd.?

, an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under various stage studies for indications, such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73, a Pan-KRAS inhibitor for indications, including PDAC, CRC, and NSCLC; JAB-2485 Aurora A inhibitor, JAB-30355 p53 Y220C reactivator, JAB-BX102 CD73 mAb inhibitor, JAB-26766 PARP 7 inhibitor, and JAB-BX300 LIF inhibitor under trials for solid tumor indications; and JAB-24114, a glutamine-utilizing enzyme for solid tumors and hematological malignancies. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 653.10M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (43)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

ABUSSmall Cap / 647M market cap
Arbutus Biopharma Corp
Compare
MDXGSmall Cap / 646M market cap
MiMedx Group Inc
Compare
ANNXSmall Cap / 646M market cap
Annexon Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap653.10M
P/E RatioN/A
Dividend YieldN/A
Beta0.566
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.